498 related articles for article (PubMed ID: 18235113)
1. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
Korn EL; Liu PY; Lee SJ; Chapman JA; Niedzwiecki D; Suman VJ; Moon J; Sondak VK; Atkins MB; Eisenhauer EA; Parulekar W; Markovic SN; Saxman S; Kirkwood JM
J Clin Oncol; 2008 Feb; 26(4):527-34. PubMed ID: 18235113
[TBL] [Abstract][Full Text] [Related]
2. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials.
Philip PA; Chansky K; LeBlanc M; Rubinstein L; Seymour L; Ivy SP; Alberts SR; Catalano PJ; Crowley J
Clin Cancer Res; 2014 Aug; 20(16):4176-85. PubMed ID: 24914040
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
[TBL] [Abstract][Full Text] [Related]
4. Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients.
Gimotty PA; Guerry D; Flaherty K
J Clin Oncol; 2008 Feb; 26(4):517-8. PubMed ID: 18235111
[No Abstract] [Full Text] [Related]
5. Survival and prognostic factors in patients with brain metastases from malignant melanoma.
Meier S; Baumert BG; Maier T; Wellis G; Burg G; Seifert B; Dummer R
Onkologie; 2004 Apr; 27(2):145-9. PubMed ID: 15138346
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
7. Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.
Flaherty LE; Liu PY; Unger J; Sondak VK
Am J Clin Oncol; 1997 Dec; 20(6):600-4. PubMed ID: 9391549
[TBL] [Abstract][Full Text] [Related]
8. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
10. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
[TBL] [Abstract][Full Text] [Related]
11. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis.
Ny L; Hernberg M; Nyakas M; Koivunen J; Oddershede L; Yoon M; Wang X; Guyot P; Geisler J
Acta Oncol; 2020 Jul; 59(7):833-844. PubMed ID: 32285732
[No Abstract] [Full Text] [Related]
13. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
[TBL] [Abstract][Full Text] [Related]
14. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
15. Analysis of tumor burden versus progression-free survival for Phase II decision making.
Fridlyand J; Kaiser LD; Fyfe G
Contemp Clin Trials; 2011 May; 32(3):446-52. PubMed ID: 21266203
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China.
Hao M; Zhao G; Du X; Yang Y; Yang J
Tumour Biol; 2016 Aug; 37(8):10339-48. PubMed ID: 26846098
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study.
Petrella TM; Tozer R; Belanger K; Savage KJ; Wong R; Smylie M; Kamel-Reid S; Tron V; Chen BE; Hunder NN; Hagerman L; Walsh W; Eisenhauer EA
J Clin Oncol; 2012 Sep; 30(27):3396-401. PubMed ID: 22915661
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
Anouti B; Althouse S; Durm G; Hanna N
Clin Lung Cancer; 2020 May; 21(3):288-293. PubMed ID: 32143966
[TBL] [Abstract][Full Text] [Related]
20. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials.
Unger JM; Flaherty LE; Liu PY; Albain KS; Sondak VK
Cancer; 2001 Mar; 91(6):1148-55. PubMed ID: 11267960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
